Results: 4

1.
Figure 3.

Figure 3. From: A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma.

Progression-free survival (PFS) plotted by the Kaplan-Meier method. The median PFS time was 13 months.

Tabraiz A. Mohammed, et al. Oncologist. 2011 June;16(6):835-843.
2.
Figure 2.

Figure 2. From: A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma.

Overall survival plotted by the Kaplan-Meier method. The median overall survival has not been reached after a maximum follow-up time of 21 months.

Tabraiz A. Mohammed, et al. Oncologist. 2011 June;16(6):835-843.
3.
Figure 1.

Figure 1. From: A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma.

Waterfall plot of tumor marker change from baseline. The majority of patients experienced an improvement in their tumor markers with 3 out of 7 approaching a near 100% improvement from baseline.

Tabraiz A. Mohammed, et al. Oncologist. 2011 June;16(6):835-843.
4.
Figure 4.

Figure 4. From: A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma.

Gene expression analysis for NOTCH1 in pretreatment and post-treatment biopsies. Each of pre-VPA and on VPA bars represents the mean of biopsies from four different patients. NOTCH1–3 expression folds were obtained by dividing normalized expressions of unknown samples (pre- or on VPA) by normalized expression of negative control comprising gastrointestinal carcinoid cell line (BON). Fold expression was then plotted as average ± SEM. The differences in NOTCH1 expressions between pre-VPA and on VPA treatment groups were statistically significant (p < .05). Abbreviation: VPA, valproic acid.

Tabraiz A. Mohammed, et al. Oncologist. 2011 June;16(6):835-843.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk